Oric Pharmaceuticals (NASDAQ:ORIC) used a fireside chat at the Guggenheim Biotech Conference to outline development priorities for its two lead oncology programs and to reiterate its expected 2025 milestones, including plans to initiate a Phase 3 study in prostate cancer in the first half of the year. Company focus and lead programs Chief Business Officer […]